Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605214 | 1.00 | PTGES (0.51) | PTGESMAOBLRRK2PTGER1FOLH1 | |
| SCHEMBL28317383 | 0.87 | NPC1 (0.53) | PTGESMAOBLRRK2PTGER1FOLH1 | |
| SCHEMBL4473413 | 0.87 | MAOB (0.61) | MAOBFOLH1MAOACYP1A2LMNA | |
| SCHEMBL16898127 | 0.87 | FOLH1 (0.58) | PTGESLRRK2PTGER1FOLH1CYP1A2 | |
| SCHEMBL21505214 | 0.86 | PTGES (0.49) | PTGESMAOBLRRK2PTGER1FOLH1 | |
| SCHEMBL4481452 | 0.84 | FFAR4 (0.51) | MAOBLRRK2PTGER1FOLH1MAOA | |
| SCHEMBL21436822 | 0.84 | MCL1 (0.55) | MAOBPTGER1FOLH1 | |
| SCHEMBL11355488 | 0.84 | PTGER1 (0.54) | MAOBLRRK2PTGER1FOLH1 | |
| SCHEMBL1106947 | 0.84 | MAOB (0.61) | PTGESMAOBLRRK2MAOA | |
| SCHEMBL30361330 | 0.84 | MAOB (0.61) | PTGESMAOBLRRK2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | PTGES 44/4885MAOB 3407/4885LRRK2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.